Except for the 5% of patients with microsatellite instable (MSI) tumors who may benefit from first-line immunotherapy, the standard treatment of stage IV microsatellite stable (MSS) CRC is still based on the combination of different systemic chemotherapies (FOLFOX, FOLFIRI or FOLRINOX) and targeted agents (anti-EGFR or anti-VEGF) according to patient and tumor characteristics (molecular biology, tumor sidedness and pattern of metastatic spread) [7]. The gene discussed is VEGFA; the disease is neoplasm.